Fig. 1From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital schoolTornado diagram showing incremental cost-effectiveness ratio after the inclusion of minimum and maximum values of the parameters to the modelBack to article page